Rapid evolution of the neutralizing antibody response to HIV type 1 infection

A recombinant virus assay was used to characterize in detail neutralizing antibody responses directed at circulating autologous HIV in plasma. Examining serial plasma specimens in a matrix format, most patients with primary HIV infection rapidly generated significant neutralizing antibody responses to early (0–39 months) autologous viruses, whereas responses to laboratory and heterologous primary strains were often lower and delayed. Plasma virus continually and rapidly evolved to escape neutralization, indicating that neutralizing antibody exerts a level of selective pressure that has been underappreciated based on earlier, less comprehensive characterizations. These data argue that neutralizing antibody responses account for the extensive variation in the envelope gene that is observed in the early months after primary HIV infection.

[1]  K. Kobayashi,et al.  Antigenic drift of equine infectious anemia virus in chronically infected horses , 2005, Archiv für die gesamte Virusforschung.

[2]  Peter D. Kwong,et al.  HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.

[3]  N. Haigwood,et al.  Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies , 2002, Journal of Virology.

[4]  D. Burton,et al.  The antiviral activity of antibodies in vitro and in vivo , 2001, Advances in Immunology.

[5]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[6]  B. Korber,et al.  Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.

[7]  Robert A. Rasmussen,et al.  Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.

[8]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[9]  Douglas D. Richman,et al.  Viral Dynamics of Acute HIV-1 Infection , 1999, The Journal of experimental medicine.

[10]  J. Mascola,et al.  Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.

[11]  D. Montefiori,et al.  Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors. , 1999, The Journal of infectious diseases.

[12]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[13]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[14]  N. Haigwood,et al.  Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.

[15]  Peter D. Kwong,et al.  The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.

[16]  D. Burton A vaccine for HIV type 1: the antibody perspective. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Alan S. Perelson,et al.  Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.

[18]  J. Bradac,et al.  Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. , 1997, The Journal of infectious diseases.

[19]  E A Emini,et al.  Recombinant human monoclonal antibody IgG1b12 neutralizes diverse human immunodeficiency virus type 1 primary isolates. , 1997, AIDS research and human retroviruses.

[20]  D. Richman,et al.  Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients , 1996, Journal of virology.

[21]  S. J. Clark,et al.  HIV-specific cellular and humoral immune responses in primary HIV infection. , 1996, AIDS research and human retroviruses.

[22]  A. Trkola,et al.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG , 1995, Journal of virology.

[23]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[24]  J. Moore,et al.  Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1 , 1994, Journal of virology.

[25]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[26]  T. Wrin,et al.  Neutralizing antibody responses to autologous and heterologous isolates of human immunodeficiency virus. , 1994, Journal of acquired immune deficiency syndromes.

[27]  R. Desrosiers,et al.  Simian immunodeficiency virus mutants resistant to serum neutralization arise during persistent infection of rhesus monkeys , 1993, Journal of virology.

[28]  D. Katzenstein,et al.  A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. , 1993, The Journal of infectious diseases.

[29]  K. Ariyoshi,et al.  Is clearance of HIV-1 viraemia at seroconversion mediated by neutralising antibodies? , 1992, The Lancet.

[30]  J. Hansen,et al.  Autologous HIV‐1 Neutralizing Antibodies: Emergence of Neutralization‐Resistant Escape Virus and Subsequent Development of Escape Virus Neutralizing Antibodies , 1992, Journal of acquired immune deficiency syndromes.

[31]  Y. Masuho,et al.  Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. , 1991, Virology.

[32]  M. Wainberg,et al.  Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera. , 1990, The Journal of infectious diseases.

[33]  J. Levy,et al.  Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals , 1990, Journal of virology.

[34]  J. Albert,et al.  Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.

[35]  A. Dalgleish,et al.  Variable and conserved neutralization antigens of human immunodeficiency virus , 1986, Nature.

[36]  D. Griffin,et al.  Antigenic shift of visna virus in persistently infected sheep. , 1977, Science.